These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36624662)

  • 1. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
    Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
    J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based simulation to support the extended dosing regimens of atezolizumab.
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
    Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
    J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
    Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
    Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
    Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
    Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
    Kicken MP; Deenen MJ; Moes DJAR; Hendrikx JJMA; van den Borne BEEM; Dumoulin DW; van der Wekken AJ; van den Heuvel MM; Ter Heine R
    Target Oncol; 2024 Sep; 19(5):779-787. PubMed ID: 39085452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
    Marolleau S; Mogenet A; Boeri C; Hamimed M; Ciccolini J; Greillier L
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1795-1803. PubMed ID: 38011601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
    Puszkiel A; Bianconi G; Pasquiers B; Balakirouchenane D; Arrondeau J; Boudou-Rouquette P; Bretagne MC; Salem JE; Declèves X; Vidal M; Kramkimel N; Guegan S; Aractingi S; Huillard O; Alexandre J; Wislez M; Goldwasser F; Blanchet B
    Br J Cancer; 2024 May; 130(11):1866-1874. PubMed ID: 38532102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies.
    Penkov K; Bondarenko I; Saenko DV; Kulyaba Y; Guo J; Gong Y; Yamamoto N; Hotko YS; Boyko V; Fadeeva NV; Ursol GM; Ahn HK; Kislov NV; Shen CI; Davis C; Kowalski K; Michelon E; Pavlov D; Hirohashi T; Cho BC
    Ther Adv Med Oncol; 2024; 16():17588359241274592. PubMed ID: 39281971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
    Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Lee JB; Broadwell A; Fan Y; Hu C; Adedokun OJ; Chakravarty SD; Zhou H; Xu Z; Leu JH
    Clin Ther; 2022 Mar; 44(3):457-464.e2. PubMed ID: 35183373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
    Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
    J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
    Liu SN; Lu T; Jin JY; Li C; Girish S; Melnikov F; Badovinac Crnjevic T; Machackova Z; Restuccia E; Kirschbrown WP
    J Clin Pharmacol; 2021 Aug; 61(8):1096-1105. PubMed ID: 33719071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.